[go: up one dir, main page]

PA8773501A1 - Inhibidores de canales de iones - Google Patents

Inhibidores de canales de iones

Info

Publication number
PA8773501A1
PA8773501A1 PA20088773501A PA8773501A PA8773501A1 PA 8773501 A1 PA8773501 A1 PA 8773501A1 PA 20088773501 A PA20088773501 A PA 20088773501A PA 8773501 A PA8773501 A PA 8773501A PA 8773501 A1 PA8773501 A1 PA 8773501A1
Authority
PA
Panama
Prior art keywords
compositions
compounds
procedures
inhibition
treatment
Prior art date
Application number
PA20088773501A
Other languages
English (en)
Inventor
Alan Swain Nigel
Edward Marron Brian
Christopher Fritch Paul
John Markworth Christopher
Thomas Maynard Andrew
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PA8773501A1 publication Critical patent/PA8773501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/42—Benzene-sulfonamido pyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE PROPORCIONAN COMPUESTOS, COMPOSICIONES Y PROCEDIMIENTOS QUE SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES MEDIANTE LA INHIBICION DEL FLUJO DE IONES SODIO A TRAVES DE CANALES DE SODIO DEPENDIENTES DE VOLTAJE. MAS PARTICULARMENTE, LA INVENCION PROPORCIONA ARILSULFONAMIDAS SUSTITUIDAS, COMPOSICIONES QUE COMPRENDEN ESTOS COMPUESTOS, ASI COMO PROCEDIMIENTOS PARA USAR ESTOS COMPUESTOS O COMPOSICIONES EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL O PERIFERICO, PARTICULARMENTE DOLOR Y DOLOR CRONICO, MEDIANTE EL BLOQUEO DE CANALES DE SODIO ASOCIADO CON LA APARICION O REPARACION DE LAS AFECCIONES INDICADAS. LOS COMPUESTOS, COMPOSICIONES Y PROCEDIMIENTOS DE LA PRESENTE INVENCION SON DE UTILIDAD PARTICULAR PARA TRATAR DOLOR NEUROPATICO O INFLAMATORIO MEDIANTE LA INHIBICION DEL FLUJO DE IONES A TRAVES DE UN CANAL DE SODIO DEPENDIENTE DE VOLTAJE.
PA20088773501A 2007-03-23 2008-03-24 Inhibidores de canales de iones PA8773501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89673507P 2007-03-23 2007-03-23
US3532408P 2008-03-10 2008-03-10

Publications (1)

Publication Number Publication Date
PA8773501A1 true PA8773501A1 (es) 2009-04-23

Family

ID=39788940

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088773501A PA8773501A1 (es) 2007-03-23 2008-03-24 Inhibidores de canales de iones

Country Status (14)

Country Link
US (2) US8357711B2 (es)
EP (1) EP1995241B1 (es)
JP (1) JP5361857B2 (es)
AR (1) AR065824A1 (es)
AT (1) ATE461177T1 (es)
CA (1) CA2681572C (es)
CL (1) CL2008000835A1 (es)
DE (1) DE602008000809D1 (es)
ES (1) ES2340640T3 (es)
PA (1) PA8773501A1 (es)
PE (1) PE20090237A1 (es)
TW (1) TW200845969A (es)
UY (1) UY30978A1 (es)
WO (1) WO2008118758A1 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3034494A1 (en) * 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
SI2197849T1 (sl) * 2007-10-09 2013-05-31 Merck Patent Gmbh Derivati n-(pirazol-3-il)-benzamida kot aktivatorji glukokinaze
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010033824A1 (en) * 2008-09-19 2010-03-25 Icagen, Inc. Sulfonamide derivatives as inhibitors of ion channels
WO2010035166A1 (en) * 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
EP2349270B1 (en) * 2008-10-21 2015-09-09 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
KR20140071518A (ko) * 2009-05-01 2014-06-12 라퀄리아 파마 인코포레이티드 Ｔｒｐｍ8 길항제로서의 설파모일 벤조산 유도체
KR101605061B1 (ko) * 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
AU2010310518A1 (en) * 2009-10-22 2012-06-07 Vanderbilt University mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
WO2011104649A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues
JP2013522249A (ja) * 2010-03-16 2013-06-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング モルホリニルキナゾリン
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
CA2803118C (en) * 2010-07-09 2015-11-03 Pfizer Limited Sulfonamide derivatives as nav 1.7 inhibitors
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化学化合物
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
WO2012053186A1 (en) * 2010-10-18 2012-04-26 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
JP5595616B2 (ja) 2011-04-05 2014-09-24 ファイザー・リミテッド トロポミオシン関連キナーゼ阻害薬としてのピロロ［２，３−ｄ］ピリミジン誘導体
JP5898767B2 (ja) 2011-07-13 2016-04-06 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ エンケファリン類似体
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
SG11201401032YA (en) 2011-10-26 2014-07-30 Pfizer Ltd (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
CA2853231C (en) 2011-10-28 2020-08-04 Inhibitaxin Limited Pyridazine derivatives with autotaxin activity for use in therapy
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013088315A1 (en) 2011-12-15 2013-06-20 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
WO2013102826A1 (en) 2012-01-04 2013-07-11 Pfizer Limited N-aminosulfonyl benzamides
CA2861439C (en) 2012-02-03 2016-07-12 Pfizer Inc. Benzimidazole and imidazopyridine derivatives as sodium channel modulators
RU2632899C2 (ru) * 2012-04-25 2017-10-11 Раквалиа Фарма Инк. Амидопроизводные как блокаторы ttx-s
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
RU2015103913A (ru) 2012-07-06 2016-08-27 Дженентек, Инк. N-замещенные бензамиды и способы их применение
US20150250785A1 (en) 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
CA2885253A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
EP2906558B1 (en) 2012-10-15 2020-09-02 Daewoong Pharmaceutical Co., Ltd. Sodium channel blockers, preparation method thereof and use thereof
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014176142A1 (en) * 2013-04-23 2014-10-30 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
CA2934010A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
EP3131891A1 (en) 2014-04-15 2017-02-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
AU2016330503B2 (en) 2015-09-28 2021-04-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
US10538523B2 (en) 2015-12-10 2020-01-21 Pfizer Limited 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
BR112018012408A2 (pt) 2015-12-18 2018-12-04 Merck Sharp & Dohme ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica?
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
EP3558992A4 (en) 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)
US11117858B2 (en) 2017-01-11 2021-09-14 The General Hospital Corporation Voltage gated sodium channel imaging agents
EP3601273B1 (en) 2017-03-24 2021-12-01 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN110740915B (zh) * 2017-06-27 2022-11-15 本田技研工业株式会社 行驶控制系统以及车辆的控制方法
CA3073801C (en) 2017-08-25 2023-07-11 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for ameliorating pain
CN112041313A (zh) 2018-02-26 2020-12-04 基因泰克公司 吡啶-磺酰胺化合物及其针对疼痛和相关疾患的用途
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN108752274B (zh) * 2018-07-25 2022-03-29 遂成药业股份有限公司 一种5-异喹啉磺酰氯的制备方法
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
SG11202109713PA (en) 2019-03-11 2021-10-28 Nocion Therapeutics Inc Ester substituted ion channel blockers and methods for use
EP3938345A4 (en) 2019-03-11 2023-01-18 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
WO2020185881A1 (en) 2019-03-11 2020-09-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP4054586A4 (en) 2019-11-06 2023-11-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3155586A1 (en) 2019-11-06 2021-05-14 Bridget M. Cole Charged ion channel blockers and methods for use
CN115279731B (zh) 2020-03-11 2024-09-13 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US20240246932A1 (en) * 2021-05-07 2024-07-25 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CN115015310B (zh) * 2022-05-23 2024-12-10 宁波大学 一种巯基化合物的分析方法
KR20240172702A (ko) * 2023-05-30 2024-12-10 삼진제약주식회사 신규한 벤즈아미드 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6673824B1 (en) 1992-05-06 2004-01-06 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
US6172085B1 (en) 1996-08-29 2001-01-09 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators
IL131318A (en) 1997-04-28 2004-08-31 Encysive Pharmaceuticals Inc Pharmaceutically acceptable salts of sulfonamides for treatment of endothelin-mediated disorders
GB9800750D0 (en) * 1998-01-14 1998-03-11 Lilly Co Eli Pharmaceutical compound
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
ATE295831T1 (de) 1999-03-10 2005-06-15 Shionogi & Co Medizinische zubereitungen mit (2.2.1) und (3.1.1)bicycloskelett die antagonisten für sowohl pgd 2? als auch txa 2? rezeptoren sind
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
CN1372541A (zh) 1999-09-01 2002-10-02 阿文蒂斯药物德国有限公司 磺酰基甲酰胺衍生物、其制备方法及其作为药物的应用
EP1244657B1 (en) 1999-12-31 2004-12-29 Encysive Pharmaceuticals Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
ES2215893T3 (es) 2000-03-17 2004-10-16 Bristol-Myers Squibb Pharma Company Derivados de beta-aminoacidos como inhibidores de metaloproteasas de matriz y tnf-alfa.
CA2407088A1 (en) 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. Beta-secretase inhibitors
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001270029A1 (en) 2000-06-21 2002-01-02 Smith Kline Beecham Corporation Macrophage scavenger receptor antagonists
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
DE60236541D1 (de) 2001-11-22 2010-07-08 Biovitrum Ab Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BR0214344A (pt) 2001-11-22 2004-09-14 Biovitrum Ab Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
JP2003292485A (ja) * 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
WO2004048319A1 (en) 2002-11-25 2004-06-10 7Tm Pharma A/S Novel benzamide compounds for use in mch receptor related disorders
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
ATE482200T1 (de) 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
FR2856133B1 (fr) 2003-06-16 2005-11-04 Commissariat Energie Atomique Dispositif d'exploration de canalisations avec tete centree
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301888D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use VII
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
AU2004255342C1 (en) 2003-07-08 2009-05-14 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US8202861B2 (en) * 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
US20080015223A1 (en) 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007055941A2 (en) 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
MX2008013203A (es) 2006-04-12 2008-10-22 Wyeth Corp Analogos de anilino-pirimidina fenilo y benzotiofeno.

Also Published As

Publication number Publication date
JP2010522242A (ja) 2010-07-01
EP1995241A1 (en) 2008-11-26
PE20090237A1 (es) 2009-03-29
DE602008000809D1 (de) 2010-04-29
US8741934B2 (en) 2014-06-03
JP5361857B2 (ja) 2013-12-04
US8357711B2 (en) 2013-01-22
AR065824A1 (es) 2009-07-01
TW200845969A (en) 2008-12-01
CA2681572C (en) 2014-02-11
US20090143358A1 (en) 2009-06-04
UY30978A1 (es) 2008-10-31
EP1995241B1 (en) 2010-03-17
ATE461177T1 (de) 2010-04-15
ES2340640T3 (es) 2010-06-07
CA2681572A1 (en) 2008-10-02
CL2008000835A1 (es) 2008-10-03
US20130072471A1 (en) 2013-03-21
WO2008118758A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
PA8773501A1 (es) Inhibidores de canales de iones
CL2021001171A1 (es) Compuestos de anillo fusionado.
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
GT201100278A (es) Inhibidores del canal de potasio medular externo renal
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
UY30098A1 (es) Compuestos de tiazol y metodos de uso
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
PA8842101A1 (es) Heteroarilos sustituidos
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
MA31564B1 (fr) Inhibition par arni de l'expression du canal alpha-enac
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
HN2008001532A (es) Derivados de dihidropirazolopirimidina
HN2011000193A (es) Derivados de piridazina como inhibidores de smo
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CR10355A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
CR8879A (es) Bifeniltiazolcarboxamidas
UY32730A (es) Inhibidores de cyp17
CR11017A (es) Anticuerpos anti-robo4 y sus usos
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
TR201818983T4 (tr) İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri